Apparatus and methods for taking blood glucose measurements and recommending insulin doses
Inventors
Bielawa, Holly • Demetris, Carissa • Goebel, James • Morton, Carol Treat • Pomorski, Michelle • Puricelli, Thomas • Rodgers, Jim • Bashan, Eran • Hodish, Israel • Monteith, John R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10007760-B2
Publication Date
2018-06-26
Expiration Date
Abstract
The present disclosure related to an apparatus that may be used for taking blood glucose measurements and providing individualized insulin dose recommendations wherein the apparatus is easy to use and facilitates improved diabetes control in patients. Also disclosed are related methods.
Core Innovation
The invention relates to an insulin-management blood glucose measurement apparatus that translates a patient’s current blood glucose level measurement into successive on-screen displays. The processor causes the successive display of information corresponding to the patient’s current blood glucose level measurement, an event associated with the current blood glucose level measurement, and a recommended insulin dose.
The apparatus includes a plurality of buttons that a user activates to navigate and modify the displayed information. A first button enables the user to selectively cycle through the successive information displays, while second and third buttons enable the user to selectively alter information displayed in one or more of the successive information displays.
The continuously displayed indicia are positioned in alignment with the first button, and the successively displayed information is positioned in alignment with the second and third buttons to simplify navigation and modification. The document also describes automatic progression to an event screen when the first button is not actuated within a predetermined period, user override of the recommended insulin dose, optional default event selection based on time of day, and a safety feature preventing insulin recommendations at low glucose levels.
Claims Coverage
The document provides two independent claims (clm-00001 and clm-00017). Across these independent claims, the core inventive features are the successive display of blood glucose, an associated event, and a recommended insulin dose, combined with continuous and simultaneous display of aligned indicia controlled by user buttons for cycling, and in one independent claim, altering.
Successive insulin-management information display
A processor causes the successive display of information corresponding to a patient's current blood glucose level measurement as determined from a sample of the patient's blood, an event associated with the said current blood glucose level measurement, and a recommended insulin dose.
Continuous and simultaneous display with indicia
The processor causes the continuous and simultaneous display of indicia corresponding to the patient's current blood glucose level measurement, an event associated with the current blood glucose level measurement, and a recommended insulin dosage while simultaneously causing the display of the successive information.
Aligned navigation via user buttons
The apparatus includes a plurality of buttons including a first button operative to enable a user to selectively cycle through the successive information displays and second and third buttons operative to enable a user to selectively alter the information displayed in one or more of the successive information displays, with continuously displayed indicia aligned with the first button and successively displayed information aligned with the second and third buttons.
Cycle-through control using a single button
An apparatus includes at least one button operative to enable a user to selectively cycle through the successive information displays on the display screen.
Both independent claims cover a display-driven insulin-management apparatus that successively displays current blood glucose measurement, an event associated with that measurement, and a recommended insulin dose, while continuously and simultaneously displaying corresponding indicia. Claim clm-00001 additionally specifies button-controlled cycling and alteration with alignment between indicia and the first/second/third buttons, while clm-00017 specifies cycling using at least one button.
Stated Advantages
Simplifies navigation and modification of event/carbohydrate/dose inputs through continuous indicia aligned with user buttons.
Automatically advances the display to the event screen if a first button is not actuated within a predetermined period.
Allows user override of the recommended insulin dose.
Supports a safety feature preventing recommendations at low glucose levels (e.g., less than 65 mg/dL).
Defines usability/proficiency targets for intended users becoming proficient after test uses.
Documented Applications
Insulin-management blood glucose measurement use where a patient’s current blood glucose level measurement is associated with an event and used to display a recommended insulin dose on a display screen.
Interactive display workflow for viewing and cycling through event-associated information and a recommended insulin dose using user buttons, including automatic display transition when a button is not actuated within a predetermined period.
Usability/proficiency testing context in which intended users achieve defined proficiency thresholds after one to three test uses.
Interested in licensing this patent?